Valuation: Cerenome, Inc.

Market Cap 15.41M 13.43M 12.65M 11.52M 21.6M 1.48B 21.63M 152M 58.4M 752M 57.87M 56.59M 2.43B P/E 2026 *
-0.43x
P/E 2027 * -0.82x
Enterprise Value 15.41M 13.43M 12.65M 11.52M 21.6M 1.48B 21.63M 152M 58.4M 752M 57.87M 56.59M 2.43B EV / Sales 2026 *
2.67x
EV / Sales 2027 * 0.8x
Free-Float
98.2%
Yield 2026 *
-
Yield 2027 * -
1 day-2.22%
1 week-7.84%
Current month-29.09%
1 month-34.86%
3 months-49.75%
6 months-67.26%
Current year-84.39%
1 week 1.96
Extreme 1.96
2.23
1 month 1.96
Extreme 1.96
3.25
Current year 1.96
Extreme 1.96
15.32
1 year 1.96
Extreme 1.96
23.42
3 years 1.96
Extreme 1.96
69.5
5 years 1.96
Extreme 1.96
810
10 years 1.96
Extreme 1.96
401,252.51
Manager TitleAgeSince
Chief Executive Officer 64 02/04/2014
Director of Finance/CFO 52 06/02/2020
Chief Tech/Sci/R&D Officer - 21/10/2025
Director TitleAgeSince
Director/Board Member 64 01/10/2002
Chairman 77 25/01/2018
Director/Board Member 66 01/01/2020
Date Insider Type Main position Quantity % Market Cap. Importance
01/07/26 Exercice

Director

1,844 0.0269%
01/07/26 Exercice

Chief Financial Officer

5,970 0.0870%
01/07/26 Exercice

Director

1,844 0.0269%
Change 5-day change 1-year change 3-year change Capi.($)
-3.45%-7.84%-81.10%-93.55% 15.41M
+0.59%+2.73%+1.48%+28.74% 46.28B
+1.06%+1.56%+43.64%+35.46% 43.85B
+0.99%-6.05%+333.91%+532.22% 40.93B
+4.06%+3.19%+8.08%+94.43% 39.89B
+1.11%+1.80%+11.52%+43.15% 29.5B
+2.31%+4.91%+25.41%+159.40% 17.09B
+1.04%-9.79% - - 15.55B
+2.12%+8.18%+24.54%+41.21% 15.22B
+1.12%+26.54%-8.33% - 14.05B
Average +1.26%+2.30%+39.91%+105.13% 26.24B
Weighted average by Cap. +1.63%+2.08%+68.88%+142.01%

Financials

2026 *2027 *
Net sales 5.77M 5.03M 4.74M 4.32M 8.09M 553M 8.1M 56.78M 21.88M 282M 21.69M 21.2M 909M 19.14M 16.69M 15.72M 14.31M 26.84M 1.83B 26.87M 188M 72.55M 934M 71.9M 70.31M 3.01B
Net income -32.26M -28.13M -26.49M -24.12M -45.23M -3.09B -45.29M -317M -122M -1.57B -121M -118M -5.08B -19.05M -16.61M -15.65M -14.25M -26.72M -1.83B -26.75M -187M -72.23M -930M -71.58M -69.99M -3B
Net Debt - -
Logo Cerenome, Inc.
Cerenome, Inc., formerly Plus Therapeutics, Inc., is a healthcare company. The Company is focused on central nervous system (CNS) cancers through three business areas: precision diagnostics, targeted radiopharmaceutical therapeutics, and proprietary data analytics. Its subsidiary CNSide Diagnostics, LLC, develops and commercializes proprietary laboratory-developed tests, including the CNSide cerebrospinal fluid (CSF) assay platform, designed to identify, characterize and monitor tumor cells in patients with CNS cancers. Its lead product candidate, rhenium (186Re) obisbemeda (REYOBIQ), is designed for CNS cancers, including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC), through direct localized delivery utilizing tissue access methods, including convection-enhanced delivery (CED) and others. Its Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat primary and metastatic solid organ cancers.
Employees
28
Date Price Change Volume
21/09/26 $2.000 -1.49% 54,868
18/09/26 $2.030 0.00% 60,227
17/09/26 $2.030 -0.49% 76,859
16/09/26 $2.040 -3.77% 65,775
15/09/26 $2.120 -2.30% 96,271
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.030USD
Average target price
32.50USD
Spread / Average Target
+1,500.99%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CNSY Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!